Trial reportParasitology research2025
Molecular-based assessment of the efficacy of anthelminthic combination regimens for the treatment of Strongyloides stercoralis in Gabon.
Trial report in Parasitology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04326868 (Human Soil Transmitted Helminths), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To assess the efficacy of three proposed anthelminthic combination regimens for the treatment of strongyloidiasis using real-time polymerase chain reaction (real-time PCR) diagnostic method. Methods: We conducted an interventional randomized assessor-blinded clinical trial in which participants positive for strongyloidiasis were treated with three different therapeutic regimens: albendazole (ABZ) once a day for three days, and ABZ on days 1 and 3 associated with mebendazole (MBZ) or pyrantel (PYR) on day 2, respectively. All participants were seen after treatment for drug efficacy assessment. Microscopy methods and real-time PCR analysis were used for the diagnosis of strongyloidiasis, and the proportions of positive cases were compared between the two tests. Cure rate (CR) was reported to describe the efficacy of each treatment regimen. Risk factors for strongyloidiasis were assessed. Results: Fifty-nine of the 272 participants included in the study were positive for S. stercoralis infection at baseline as determined by either microscopy and/or PCR. The PCR-positive cases were 3.92 times higher than microscopy positive cases. The microscopy- and PCR-based corrected CRs were 100% and 68% (95%CI: 53–81), respectively. The CR was greater for the ABZ-ABZ-ABZ (77%; 95%CI: 55–92) than for the ABZ-MBZ-ABZ (69%; 95%CI: 39–91) or ABZ-PYR-ABZ (50%; 95%CI: 21–79) regimens, but the difference was not statistically significant. None of the factors investigated (age, sex, or location) were associated with either being infected with S. stercoralis in our cohort or being cured. Conclusion: Our findings indicate that on the one hand, the need for a more sensitive method than current microscopy for the diagnosis of strongyloidiasis and on the other hand ABZ alone repeated over three days has better efficacy for the treatment of strongyloidiasis than alternating ABZ with MBZ or PYR for the same period of treatment. However, its efficacy remains limited, raising the necessity for the development of alternative treatments. Clinical trial: Registered at ClinicalTrials.gov (NCT04326868) on March 04, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.